Shattuck Labs, Inc. (NASDAQ:STTK) Receives Consensus Recommendation of “Buy” from Brokerages

Shares of Shattuck Labs, Inc. (NASDAQ:STTK) have been given an average rating of “Buy” by the twelve research firms that are currently covering the firm, Marketbeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation, nine have given a buy recommendation and two have assigned a strong buy recommendation to the company. The average 1 year price target among analysts that have issued ratings on the stock in the last year is $12.7778.

A number of research firms have issued reports on STTK. Raymond James Financial assumed coverage on shares of Shattuck Labs in a research report on Monday, August 24th. They issued a “strong-buy” rating and a $18.00 price objective on the stock. Wall Street Zen lowered shares of Shattuck Labs from a “buy” rating to a “hold” rating in a report on Saturday, August 15th. TD Cowen raised Shattuck Labs to a “strong-buy” rating in a research note on Monday, August 24th. Needham & Company LLC boosted their price target on Shattuck Labs from $14.00 to $17.00 and gave the company a “buy” rating in a report on Monday, June 8th. Finally, Leerink Partners initiated coverage on Shattuck Labs in a research report on Monday, July 20th. They set an “outperform” rating and a $16.00 price target for the company.

Shattuck Labs Stock Performance

Shares of Shattuck Labs stock opened at $7.04 on Monday. Shattuck Labs has a 52-week low of $0.97 and a 52-week high of $8.33. The stock has a market capitalization of $706.53 million, a price-to-earnings ratio of -13.80 and a beta of 1.08. The company’s 50 day moving average price is $7.05 and its 200-day moving average price is $6.22.

Shattuck Labs (NASDAQ:STTK) last posted its quarterly earnings results on Tuesday, August 11th. The company reported ($0.12) EPS for the quarter, meeting analysts’ consensus estimates of ($0.12). As a group, equities research analysts forecast that Shattuck Labs will post -0.44 earnings per share for the current fiscal year.

Insider Activity at Shattuck Labs

In related news, Director Clay B. Siegall acquired 62,500 shares of Shattuck Labs stock in a transaction on Tuesday, June 9th. The shares were acquired at an average cost of $4.00 per share, with a total value of $250,000.00. Following the transaction, the director owned 318,608 shares in the company, valued at $1,274,432. This trade represents a 24.40% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, insider Arundathy N. Pandite sold 30,000 shares of the firm’s stock in a transaction dated Tuesday, June 30th. The stock was sold at an average price of $7.01, for a total transaction of $210,300.00. Following the completion of the sale, the insider directly owned 136,219 shares of the company’s stock, valued at approximately $954,895.19. This represents a 18.05% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 53,875 shares of company stock worth $379,305 over the last quarter. Corporate insiders own 8.79% of the company’s stock.

Institutional Inflows and Outflows

A number of large investors have recently bought and sold shares of STTK. California State Teachers Retirement System purchased a new position in shares of Shattuck Labs during the second quarter valued at approximately $41,000. Legal & General Group Plc purchased a new position in shares of Shattuck Labs in the 2nd quarter worth about $41,000. Virtu Financial LLC bought a new position in Shattuck Labs in the 3rd quarter worth about $38,000. Squarepoint Ops LLC bought a new stake in Shattuck Labs during the 3rd quarter valued at about $46,000. Finally, State of Wyoming purchased a new position in Shattuck Labs in the second quarter worth about $151,000. 58.74% of the stock is owned by hedge funds and other institutional investors.

About Shattuck Labs

Shattuck Labs, Inc (NASDAQ: STTK) is a clinical‐stage biotechnology company headquartered in Cambridge, Massachusetts. The company is focused on developing immunotherapeutic vaccines to prevent and treat substance use disorders, with an initial emphasis on opioids. Shattuck Labs employs a proprietary hapten‐carrier conjugate technology designed to generate high‐affinity drug‐specific antibodies that sequester target molecules in the bloodstream and reduce their passage across the blood‐brain barrier.

The company’s lead program targets fentanyl, a synthetic opioid responsible for a significant proportion of overdose fatalities.